IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. 
Importance of Meal Fat Content and Gall Bladder Emptying for Postprandial GLP-1 Secretion in Type 2 Diabetes Patients
This study has been completed.
Sponsor:
University Hospital, Gentofte, Copenhagen
Information provided by (Responsible Party):
David P. Sonne, University Hospital, Gentofte, Copenhagen
ClinicalTrials.gov Identifier:
NCT01374594
First received: June 14, 2011
Last updated: January 22, 2013
Last verified: January 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
PURPOSE
The goal of the present project is to unravel the importance of bile acid-induced GLP-1 secretion (via the G protein-coupled receptor TGR5) in human physiology.
In the present study the investigators examine the GLP-1 secretion in healthy subjects and in Type 2 Diabetes Mellitus (T2DM) patients. The investigators hypothesize that patients with T2DM of relatively long duration will be characterized by reduced gall bladder emptying, and, consequently, reduced intestinal TGR5 activation; resulting in attenuated postprandial GLP-1 responses (primary endpoint).
| Condition |
|---|
| Diabetes |
| Study Type: | Observational |
Further study details as provided by David P. Sonne, University Hospital, Gentofte, Copenhagen:
Primary Outcome Measures:
- GLP-1 secretion [ Time Frame: Postprandial ]
Biospecimen Description:
blood samples
| Enrollment: | 30 |
| Study Start Date: | June 2011 |
| Study Completion Date: | November 2012 |
| Primary Completion Date: | June 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
| Healthy adults |
| Type 2 diabetes |
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years (Adult, Senior) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | Yes |
| Sampling Method: | Non-Probability Sample |
Study Population
Healthy subjects and type 2 diabetes patients (T2DM)
Criteria
Inclusion Criteria: (Healthy)
- HbA1 < 6 %
- Normal haemoglobin levels
- Informed content
Inclusion Criteria: (T2DM)
- T2DM > 5 years
- Normal haemoglobin levels
- Informed content
Exclusion Criteria: (T2DM)
- Treatment with insulin, DPP-IV inhibitor or GLP-1 analogues
- Obesity (BMI > 30)
- Age > 70 years
- Gastrointestinal disease
- Nephropathy
- Liver disease
- Medication which cannot be on hold for 12h
- Gastrointestinal surgery
Exclusion Criteria: (Healthy)
- 1st degree relatives with diabetes
- Obesity (BMI > 30)
- Age > 70 years
- Gastrointestinal disease
- Nephropathy
- Liver disease
- Medication which cannot be on hold for 12h
- Gastrointestinal surgery
Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01374594
Please refer to this study by its ClinicalTrials.gov identifier: NCT01374594
Locations
| Denmark | |
| Gentofte University Hospital | |
| Hellerup, Denmark, 2900 | |
Sponsors and Collaborators
University Hospital, Gentofte, Copenhagen
More Information
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | David P. Sonne, MD, University Hospital, Gentofte, Copenhagen |
| ClinicalTrials.gov Identifier: | NCT01374594 History of Changes |
| Other Study ID Numbers: |
GAL-INK II |
| Study First Received: | June 14, 2011 |
| Last Updated: | January 22, 2013 |
ClinicalTrials.gov processed this record on August 18, 2017